A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as First-line Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)

未提供0 个研究点目标入组 68 人开始时间: 待定

适应症

试验速览

暂无简介。

•Has a histologically confirmed diagnosis of squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of cervix.
•Has persistent, recurrent, or newly diagnosed metastatic cervical cancer that is not amenable to curative treatment (surgery and/or radiation).
•If infected with human immunodeficiency virus (HIV), has well controlled HIV on antiretroviral therapy.
•If positive for hepatitis B surface antigen, has received hepatitis B virus (HBV) antiviral therapy and has undetectable HBV viral load.
•If has a history of hepatitis C virus (HCV) infection, has undetectable HCV viral load.
•Has an Eastern Cooperative Oncology Group performance status of 0 or
•Has tumor programmed cell death ligand 1 expression of combined positive score >=1.

•Has HIV infection with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
•Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing.
•Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea).
•Has uncontrolled, significant cardiovascular disease or cerebrovascular disease.
•Has received prior systemic anticancer therapy other than what is specified in this protocol.
•Is currently receiving a strong inducer/inhibitor of cytochrome P450 3A4 that cannot be discontinued for the duration of treatment with sac-TMT.
•Has a diagnosis of immunodeficiency.
•Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
•Has known active central nervous system metastases and/or carcinomatous meningitis.
•Has active autoimmune disease that has required systemic treatment in the past 2 years; replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid) is allowed.
•Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
•Has a history of stem cell/solid organ transplant.
•Has not adequately recovered from major surgery or has ongoing surgical complications.

发起方

未提供